Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo


Clinical Trial Description

Oversight Authorities:

United States: Food and Drug Administration Canada: Health Canada France: National Agency for the Safety of Medicine and Health Products Germany: Federal Institute for Drugs and Medical Devices Hungary: National Institute of Pharmacy and Nutrition Italy: Italian Medicines Agency Netherlands: Medicines Evaluation Board Poland: Chief Pharmaceutical Inspectorate Sweden: Medical Products Agency ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03759392
Study type Interventional
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email medinfo@amgen.com
Status Recruiting
Phase Phase 3
Start date April 9, 2019
Completion date March 15, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03614169 - Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB N/A
Active, not recruiting NCT03701880 - Early Use of Ivabradine in Heart Failure N/A
Enrolling by invitation NCT03479424 - Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
Completed NCT02113033 - VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients Phase 2
Recruiting NCT03209180 - Immediate Release Versus Slow Release Carvedilol in Heart Failure Phase 4
Completed NCT03870074 - CPET Predicts Long-term Survival and Positive Response to CRT
Completed NCT03951740 - Validation of Two Wrist-worn Devices for the Assessment of Energy Expenditure in Cardiac Patients. N/A
Recruiting NCT03894683 - Effect of Melatonin on Cardiovascular and Muscle Mass and Function in Patients With Heart Failure Phase 2
Completed NCT01922089 - Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Phase 2
Recruiting NCT03644446 - Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure
Recruiting NCT03746938 - First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction Phase 1
Not yet recruiting NCT03213821 - Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency N/A
Not yet recruiting NCT03332888 - Safety of HMA-CD20 in Patients With HFrEF Phase 2
Recruiting NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States
Not yet recruiting NCT03877887 - Finding Gab in the Treatment of Heart Failure in Assiut University Hospital
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Recruiting NCT03235700 - Hyperemic Efficacy of IV Adenosine in HFrEF N/A
Recruiting NCT03198585 - Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction Phase 2
Enrolling by invitation NCT03574857 - Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Phase 4
Not yet recruiting NCT03945058 - Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure N/A